Product Information
VYZULTA 0.024% OPHTH SOLUTION is a brand product labeled by Bausch & Lomb Incorporated, priced at $102.2513 per ML under NDC 24208050405. Its NADAC has been published 446 times since Mar 21, 2018.
FDA first approved this application on Nov 2, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.24 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208050405
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LATANOPROSTENE BUNODApproval Type
New Drug (NDA)
FDA Application
NDA207795FDA Approved
11/2/2017
TE Code
AB
On Market Since
11/2/2017
Price Statistics
The NADAC for VYZULTA 0.024% OPHTH SOLUTION has been published 446 times since Mar 21, 2018, and over the history we have for it it has risen 47.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $102.2513 per ML |
|---|---|
| All-time high | $102.2829 (Aug 12, 2026) |
| All-time low | $69.1524 (Jan 23, 2019) |
| 52-week high | $102.2829 |
| 52-week low | $99.2632 |
| Median price | $87.1990 |
| Average price | $86.7732 |
| Largest weekly change | +6.0% (Jan 22, 2020) |
| Weeks tracked | 446 |
| Tracking since | Mar 21, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
latanoprostene bunod market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VYZULTA 0.024% OPHTH SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for VYZULTA 0.024% OPHTH SOLUTION, manufactured by Bausch & Lomb Incorporated, is $102.2513 per ML (NDC 24208050405), effective Sep 30, 2026.
How has the price of VYZULTA 0.024% OPHTH SOLUTION changed over time?
Over the history we have for it, the NADAC for VYZULTA 0.024% OPHTH SOLUTION has risen 47.4%. It has been tracked across 446 weekly CMS publications since Mar 21, 2018.
What are the highest and lowest recorded NADAC prices for VYZULTA 0.024% OPHTH SOLUTION?
Since Mar 21, 2018, the NADAC for VYZULTA 0.024% OPHTH SOLUTION has ranged from a low of $69.1524 (Jan 23, 2019) to a high of $102.2829 (Aug 12, 2026), with a median of $87.1990 per ML.
Are there cheaper alternatives to VYZULTA 0.024% OPHTH SOLUTION?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VYZULTA 0.024% OPHTH SOLUTION in a comparable dosage form, but none are currently priced below it.
Who manufactures VYZULTA 0.024% OPHTH SOLUTION?
VYZULTA 0.024% OPHTH SOLUTION (NDC 24208050405) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.